Molecular Assemblies Announces $25.8 Million Series B Financing To Initiate Key Customer Program For Commercial Access To Fully Enzymatic Dna Synthesis
Molecular Assemblies Announces $25.8 Million Series B Financing To Initiate Key Customer Program For Commercial Access To Fully Enzymatic Dna Synthesis
03/15/22, 8:00 AM
Location
san diegoMoney raised
$25.8 million
Round Type
series b
Molecular Assemblies, Inc., today announced that it has raised a $25.8 million Series B financing with participation from new investor, Casdin Capital, and all major Series A investors, Agilent Technologies, iSelect Fund, Codexis, LYFE Capital, and Argonautic Ventures. The proceeds of the financing will be used to advance the company's proprietary enzymatic DNA synthesis technology toward early commercialization and start a key customer program later this year.
Company Info
Location
san diego, california, united states
Additional Info
Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies' technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego. For more information, please visit www.molecularassemblies.com.